EUVIMEDEUVIMED entdecken
Crossref

Targeting EZH2 attenuates the ferroptosis-mediated osteoblast–osteoclast imbalance in rheumatoid arthritis

Xuemei Piao, Xiangxiang Wu, Yixin Yan, Yongming Li, Na Li, Luan Xue, Feng He

International Immunopharmacology · 2024-12 · 143 · 113201

DOI: 10.1016/j.intimp.2024.113201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Xuemei Piao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medic…. Hauptthemen laut MEDLINE: Ferroptosis, Arthritis, Rheumatoid, Osteoblasts, Enhancer of Zeste Homolog 2 Protein. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) can regulate osteogenesis and osteoclastogenesis. This study aimed to further explore the effects of EZH2 modification on ferroptosis and the osteoblast-osteoclast balance in rheumatoid arthritis (RA) in vitro and in vivo. METHODS: Bone marrow mesenchymal stromal cells were transfected with EZH2 overexpression (oeEZH2) and EZH2 shRNA (shEZH2) plasmids with or without ferrostatin-1 (Fer-1) treatment and subjected to an osteoblast differentiation assay. The cells were then cocultured with bone marrow-derived macrophages and subjected to an osteoclast differentiation assay. Collagen-induced arthritis (CIA) mice were generated and injected with shEZH2 adeno-associated virus (AAV). RESULTS: OeEZH2 repressed osteoblast differentiation, as reflected by decreased ALP and Alizarin Red S staining and increased OPN, RUNX2, OPG and RANKL; however, shEZH2 had the opposite effects. Besides, oeEZH2 promoted osteoblast ferroptosis, as suggested by increased MDA, Fe2+, ROS, and PTGS2 but decreased GPX4 and SLC7A11; these effects could be attenuated by Fer-1 treatment. In contrast, shEZH2 ameliorated osteoblast ferroptosis. OeEZH2 subsequently increased osteoclast differentiation, as indicated by increased TRAP+ multinucleated cells, NFATC1, CTSK, and c-FOS; however, shEZH2 had the opposite effect, except that it did not regulate CTSK. In CIA mice, shEZH2 AAV decreased the clinical symptom score, histological score of cartilage, and systemic inflammation (TNF-α and IL-6) and repressed bone ferroptosis and restored the osteoblast-osteoclast balance to some extent, as reflected by immunohistochemical staining of related markers. CONCLUSION: Targeting EZH2 attenuates the ferroptosis-mediated osteoblast-osteoclast imbalance in RA, revealing its potential as a treatment target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisArthritis, RheumatoidOsteoblastsEnhancer of Zeste Homolog 2 ProteinOsteoclastsMice, Inbred DBAArthritis, ExperimentalAnimalsMiceMaleCell DifferentiationCells, CulturedHumansOsteogenesisMesenchymal Stem Cells

Stichwörter der Autor:innen

EZH2FerroptosisOsteoblast–osteoclast imbalanceRheumatoid arthritisTarget

Substanzen

Enhancer of Zeste Homolog 2 ProteinEzh2 protein, mouse

Autor:innen und Institutionen

  • Department of Rheumatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
  • Department of Internal Medicine, The Third People's Hospital of Chongming District, Shanghai 202153, China.
  • Department of Rheumatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. Electronic address: xelco@163.com.
  • The Center for Cancer Research, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: fhe@shutcm.edu.cn.

Zitieren

APA

Piao, X., Wu, X., Yan, Y., Li, Y., Li, N., Xue, L., & He, F. (2024). Targeting EZH2 attenuates the ferroptosis-mediated osteoblast–osteoclast imbalance in rheumatoid arthritis. International Immunopharmacology, 143, 113201. https://doi.org/10.1016/j.intimp.2024.113201

Vancouver

Piao X, Wu X, Yan Y, Li Y, Li N, Xue L, et al. Targeting EZH2 attenuates the ferroptosis-mediated osteoblast–osteoclast imbalance in rheumatoid arthritis. International Immunopharmacology. 2024;143:113201. doi:10.1016/j.intimp.2024.113201

BibTeX
@article{Piao2024,
  author = {Piao, Xuemei and Wu, Xiangxiang and Yan, Yixin and Li, Yongming and Li, Na and Xue, Luan and He, Feng},
  title = {Targeting EZH2 attenuates the ferroptosis-mediated osteoblast–osteoclast imbalance in rheumatoid arthritis},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {143},
  pages = {113201},
  doi = {10.1016/j.intimp.2024.113201}
}
Kostenlos starten →